Target HPV-induced cancers (HPV-16, E6 & E7 + IL-2)
TG4001, an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens.
TG4001 triggers a specific immune response that supports the recognition and destruction of cancer cells carrying the HPV viral antigens. This approach enables the body to destroy the tumours.
Based on promising Phase Ib/II data, Transgene is conducting a randomized Phase II trial of TG4001 in combination with avelumab. This study is being conducted with the alliance of Merck KGaA, Darmstadt, Germany, and Pfizer, which is supplying avelumab.